The Biotech Startup Class Of 2013: Don’t Worry, It’s A Short List
Published: Nov 19, 2013
We’ve heard a lot this year about the IPO boom for biotech companies. Even after a few high-profile blowups (Ariad, Sarepta), the public biotech stock indexes are still outperforming the Nasdaq Composite Index and S&P 500. Some biotechs have been acquired for megabucks (Onyx, ViroPharma). We’ve heard about another biotech bubble in the making. Normally, you’d expect all that wealth creation and associated excitement to ripple across the biotech industry and stimulate all kinds of exciting new biotech startups.
Hey, check out all the research scientist jobs. Post your resume today!